Cookson E J, Flannery A V, Cidlowski J A, Beynon R J
Department of Biochemistry, University of Liverpool, U.K.
Biochem J. 1992 Nov 15;288 ( Pt 1)(Pt 1):291-6. doi: 10.1042/bj2880291.
Over 95% of the pyridoxal phosphate (PLP) in skeletal is bound to one protein, glycogen phosphorylase. This, and the fact that phosphorylase constitutes approx. 5% of the soluble protein in skeletal muscle, introduce the possibility that PLP might be used as a specific label to identify degradation intermediates of the enzyme. In this investigation, we have developed immunological methods, using a monoclonal antibody to PLP and polyclonal antibodies to phosphorylase, to detect degradation intermediates in vitro and in vivo. We have identified a family of degradation intermediates of glycogen phosphorylase in the high-speed-supernatant fraction of mouse skeletal muscle. These peptides react with both types of antibodies and are in the size and concentration range expected for degradation intermediates in a model in which the committed step is followed by rapid clearance of the products. Changes in amounts of degradation intermediates are examined in physiological or pathological conditions in which the rate of degradation of phosphorylase is altered.
骨骼中的磷酸吡哆醛(PLP)超过95%与一种蛋白质——糖原磷酸化酶结合。此外,磷酸化酶约占骨骼肌可溶性蛋白质的5%,这使得PLP有可能用作识别该酶降解中间体的特异性标记。在本研究中,我们开发了免疫方法,使用针对PLP的单克隆抗体和针对磷酸化酶的多克隆抗体,来检测体内外的降解中间体。我们在小鼠骨骼肌的高速上清液部分中鉴定出了糖原磷酸化酶的一系列降解中间体。这些肽与两种抗体都发生反应,其大小和浓度范围符合一个模型中降解中间体的预期,该模型中关键步骤之后是产物的快速清除。在磷酸化酶降解速率发生改变的生理或病理条件下,检测降解中间体数量的变化。